-+ 0.00%
-+ 0.00%
-+ 0.00%
Tianyu Co., Ltd. announced that Zhejiang Nuode Pharmaceutical Co., Ltd., a wholly-owned subsidiary, recently received the “Drug Registration Certificate” for ibutinib capsules approved and issued by the State Drug Administration. The document number is H20266627, which is valid until November 17, 2031. The specification is 140 mg, and the registered classification is class 4 chemicals. The drug's sales in domestic sample hospitals and urban physical pharmacies in 2025 were about 399 million yuan. Nordisk Pharmaceuticals accepted this product in February 2025. As of October 31, 2026, the total R&D investment was about 7.620,800 yuan.
Share
Listen to the news
Tianyu Co., Ltd. announced that Zhejiang Nuode Pharmaceutical Co., Ltd., a wholly-owned subsidiary, recently received the “Drug Registration Certificate” for ibutinib capsules approved and issued by the State Drug Administration. The document number is H20266627, which is valid until November 17, 2031. The specification is 140 mg, and the registered classification is class 4 chemicals. The drug's sales in domestic sample hospitals and urban physical pharmacies in 2025 were about 399 million yuan. Nordisk Pharmaceuticals accepted this product in February 2025. As of October 31, 2026, the total R&D investment was about 7.620,800 yuan.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending